clinical trial · NCT05918913

Expanded Access Program for Revumenib

$SNDX →·—·no longer available

Relapsed/Refractory Acute LeukemiaRevumenib

brief summary

This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.

started

—

primary completion

—

completion

—

last updated

Sep 5, 2025

official title

Expanded Access Program for SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol